linjc16/ctgov huggingface dataset:
Evaluating the Response to Neoadjuvant Chemotherapy With Circulating Tumor DNA in Pancreatic Cancer

Study Overview
=================
Brief Summary
-----------------
For patients who have been diagnosed with pancreatic cancer that has not spread outside of the pancreas and nearby lymph nodes. The purpose of this research study is to understand if we are able to detect pancreatic cancer DNA in the blood stream before, during, and after treatment.

Detailed Description
-----------------
Cancer DNA in the blood stream is called circulating tumor DNA or ctDNA. The presence or absence of pancreatic cancer ctDNA in the blood stream may help clinicians to better understand pancreatic cancer behavior in response to specific treatments, like chemotherapy and surgery. Understanding how treatment alters the ctDNA can help future patients diagnosed with pancreatic cancer. The presence or absence of ctDNA or the clearance of ctDNA after treatment may help to guide further treatment decisions for cancer patients after surgery.

Official Title
-----------------
Evaluating the Response to Neoadjuvant Chemotherapy With Circulating Tumor DNA in Pancreatic Cancer

Conditions
-----------------
Pancreas Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Biopsy or cytology proven adenocarcinoma of the pancreas No clinical evidence of metastatic disease on imaging Age 18 or older Receiving chemotherapy for non-metastatic pancreatic cancer Exclusion Criteria: Biopsy proven metastatic disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients with circulating tumor DNA (ctDNA) levels as not detectable in their blood compared to number of patients with ctDNA detected. | Utilizing Tempus, a commercial laboratory ctDNA genetic profile panel investigators will analyze the number of patients who had detectable ctDNA in their blood prior to neoadjuvant chemotherapy who then had no detectable ctDNA after their chemotherapy treatment. | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Investigators will look for statistically significant correlations of ctDNA blood levels with clinical treatment responses of tumor grades, CA 19-9 units/milliliter blood level, and radiologic response by RECIST categories of complete response. | Association of ctDNA clearance with the following: pathologic treatment response per CAP tumor regression grade 0,1,2, and 3, blood level measurement of protein CA 19-9 units/milliliter, and radiologic response by tumor measurements in mm and using RECIST tumor measurement categories of complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) for all patients, and margin assessment (R0/R1 resection) in resected patients. | 12 months |
Vaginal Cleaning Using Povidone Iodine Before CS to Reduce Postoperative Wound Infection

Study Overview
=================
Brief Summary
-----------------
The aim of work to assess the effectiveness of preoperative vaginal cleansing with povidone iodine on reduction of post caesarean section wound infection Research questions: Does vaginal cleaning using povidone iodine before cesarean section has effect on reduction of postoperative wound infection??

Official Title
-----------------
Effect of Vaginal Cleaning Using Povidone Iodine Before CS to Reduce Postoperative Wound Infection

Conditions
-----------------
Cesarean Section Complications, Vaginal Infection, Postoperative Infection

Intervention / Treatment
-----------------
* Drug: 10% povidone iodine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Pregnant women who are 37 weeks gestation or more scheduled for elective cesarean section or those in labor with a limited number of vaginal examinations less than 5 times preoperatively. 2. Pregnant women who are 37 weeks gestation or more with rupture of membranes but duration less than 24 hours 3. Women consenting to be included in the study. Exclusion criteria: Abnormally invasive placenta and placenta previa. Intra-partum fever. Prolonged rupture of membranes more than 24 hours History of exposure to radiation treatment for cancer. History of Gynecological infections (PID). History of abdominal infections, e.g., peritonitis. Debilitating diseases like Diabetes mellitus, Thyroid disorders, Cushing disease, abdominal malignancy. Obesity is defined as pregnant BMI >30 kg/m2. History of wound infection or burst abdomen. History suggestive of massive bleeding during previous cesarean section. allergy to iodine-containing solutions Pregnant women with severe anemia defined as Hb <7 g/dl. Cases with intra-abdominal drain deployment are discarded. Obstructed labor with numerous vaginal examinations.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 38 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Iodine group<br>50 women who received preoperative vaginal cleansing with 10% povidone-iodine. | Drug: 10% povidone iodine<br>* 50 women who received preoperative vaginal cleansing with 10% povidone iodine.<br>* Other names: Betadine;|
| No Intervention: Control group<br>50 women who did not receive preoperative vaginal cleansing even with tap water. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative wound complication | Any sign of infection as redness, hotness and tenderness as well as pyrexia occurance in wound postoperative | 1 week |
Effectiveness of Respiratory Protection During Simulated Resuscitation: a Prospective Cohort Study

Study Overview
=================
Brief Summary
-----------------
The study hypothesizes that EHMRs with P100 filters will provide superior respiratory protection during simulated CPR compared to disposable N95 FFRs as measured by qualitative fit testing. To this end, the study is a prospective observational cohort to evaluate the effectiveness of disposable FFRs and EHMR during simulated CPR. The primary endpoint will be subject report of detection of the testing agent during a 2 minute session of simulated chest compressions on a mannequin while wearing the respiratory protection that subjects routinely wear during the course of employment.

Official Title
-----------------
Effectiveness of Respiratory Protection During Simulated Resuscitation: a Prospective Cohort Study

Conditions
-----------------
Occupational Exposure

Intervention / Treatment
-----------------
* Other: Qualitative Fit Testing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Current use of respirator within last 7 days Completed fit test with respirator within last 2 years Exclusion Criteria: Previous adverse reaction to fit testing or testing agent Development of any health problem that precludes use of a respirator since last occupational health evaluation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: N95 Filtering Facepiece Respirator<br>Subjects will wear the model of filtering facepiece respirator that they are currently approved to wear | Other: Qualitative Fit Testing<br>* Qualitative fit testing with denatonium benzoate<br>|
| Active Comparator: Elastomeric Half-Mask Respirator with P100 filters<br>Subjects will wear the model of elastomeric half mask respirator that they are currently approved to wear. | Other: Qualitative Fit Testing<br>* Qualitative fit testing with denatonium benzoate<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Subject Detection of Testing Agent | Subject reported detection of testing agent | 2 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to detection of testing agent | Time to subject reported detection of testing agent | 2 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Respirator, Cardiopulmonary resusitation
The Activity of Tissue Engineering Skin Substitutes

Study Overview
=================
Brief Summary
-----------------
The main purpose of this experiment was to evaluate the activity of tissue engineering skin substitutes safety and efficacy studies for the treatment of difficult to heal wounds

Detailed Description
-----------------
This study for 6 months for a single center, open, randomized, controlled clinical trials before and after itself, test contains preliminary screening, treatment and follow-up after discharge of the patient.After treatment in patients with early debridement, in the case of no infection of living tissue engineering skin substitute transplantation, observe the wound healing after transplantation, chronic wound evaluation activity of tissue engineering skin substitutes in the efficacy and safety of wound healing after transplantation.

Official Title
-----------------
Living Tissue Engineering Skin Substitutes Safety and Efficacy Studies for the Treatment of Difficult to Heal Wounds

Conditions
-----------------
Difficult to Heal Wounds

Intervention / Treatment
-----------------
* Biological: liveness tissue skin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Meet difficult had 1 month or more to heal the wound patients Who signed the informed consent of men or women older than 17 (pregnancy) Has the ability to care for, has the ability to self signed informed consent, 7 to 17 years old must be signed by the guardian informed consent The process of mental stability, can finish the test Exclusion Criteria: Known allergic to bovine collagen or gao min physique the wound is greater than the10cm×10cm People with mental illness, drug abusers and or other items Pregnant women,Prepare a pregnancy or breast feeding women 3 months participated in other similar experiment Serious infectious disease not controller With surgery, such as severe trauma stress situation Can not meet the requirement of the long-term follow-up of patients

Ages Eligible for Study
-----------------
Minimum Age: 17 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: liveness tissue skin<br> | Biological: liveness tissue skin<br>* liveness tissue skin safety and effectiveness for the treatment of difficult to heal wounds<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frequency of Adverse Events | Frequency and severity of Adverse Events | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relative Wound Area Regression of 40% or More at 6 Week |  | 6 week |
The Influence of Oxytocin on the Processing of Social Contact

Study Overview
=================
Brief Summary
-----------------
Social touch can convey the most potent and salient of socio-emotional signals. While the hypothalamic peptide oxytocin (OXT) has been identified as a key neurochemical mediator of grooming in some other social species, its modulatory influence on human interpersonal touch is unknown. The investigators expect that OXT augments the hedonic value of touch and that this behavioral effect is paralleled at the neural level by an increased response in brain areas mediating rewarding aspects of social touch.

Conditions
-----------------
Healthy Male Volunteers

Intervention / Treatment
-----------------
* Drug: Placebo
* Drug: Oxytocin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy male volunteers Exclusion Criteria: Current or past psychiatric disease Current or past physical illness Psychoactive medication Tobacco smokers

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Oxytocin<br>24 IU Oxytocin, intranasal application 30 min prior to the experiment | Drug: Oxytocin<br>* 24 IU Oxytocin, intranasal application 45 min prior to the experiment<br>* Other names: Syntocinon;|
| Placebo Comparator: Placebo<br>intranasal application, sodium chloride solution, 3 puffs per nostril | Drug: Placebo<br>* intranasal application, sodium chloride solution, 3 puffs per nostril<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pleasantness ratings of social touch | After each trial, subjects are asked to use a visual analog scale to rate the pleasantness of the administered touch. | 30 minutes after the nasal spray administration | 
| Blood-oxygen-level dependent signal in response to social touch | By using functional magnetic resonance imaging we want to examine oxytocin's effects on the neural correlates (BOLD signal) of social touch. | 30 minutes after the nasal spray administration | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Questionnaire measurement of mood (PANAS) and anxiety (STAI). |  | 15 minutes before the nasal spray administration and (on average) 10 minutes after the fMRI experiment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Oxytocin, fMRI
Cognitive, Emotional and Behavioural Impairments in Patients After Sars-Cov2 Infection

Study Overview
=================
Brief Summary
-----------------
Recent studies suggest cognitive, emotional and behavioural impairments occur in patients after SARS-CoV-2 infection. Problems with memory, attention, information processing and executive functions are particularly prevalent in these patients, probably due to hypothesised sensitivity of the hippocampus to the virus. Cognitive impairment is also present in patients with no neurological, neuropsychological and neuropsychiatric history. Therefore, the aim of the present study is to describe neuropsychological and neuropsychiatric features in patients recovered from moderate to severe forms of Covid-19 some weeks after hospital dismission.

Official Title
-----------------
Cognitive and Neuropsychiatric Features of COVID-19 Patients After Hospital Dismission: an Italian Sample.

Conditions
-----------------
COVID-19, Sars-CoV-2 Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Positive PCR from nasopharyngeal swab No ICU admission Exclusion Criteria: Diagnosis of neurologic or psychiatric disorders; Previous cognitive impairment; Other medical conditions negatively affecting the cognitive status.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Covid+<br> | |
| Covid-<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cognitive and neuropsychiatirc symptoms in Covid-19 patients | Prevalence of neuropsychological and neuropsychiatric impairment in patients after hospitalization in patients with Sars-Cov2 infection. | About 20 days after hospital dismission | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Covid-19, Cognition, Teleneuropsychology, Memory, Executive Functions
Improving Followup of Abnormal Colon Cancer Screening Tests

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether direct mailings to patients with positive fecal occult blood tests can increase rates of performing followup colonoscopy.

Detailed Description
-----------------
Screening programs using the fecal occult blood test (FOBT) have demonstrated a significant reduction in colorectal cancer mortality, although only when accompanied by a complete diagnostic evaluation of the colon in the setting of a positive result. 90% of patients with a positive FOBT result have completed a subsequent colonoscopy within Harvard Vanguard Medical Associates. This project will use a pre-post study design to increase the rate of followup colonoscopy in the setting of positive FOBT results. Patients in the intervention group will receive a personalized mailing highlighting their positive result and need for colonoscopy, followed by telephone outreach from a centralized gastroenterology scheduling office. The primary outcome will be the performance of colonoscopy, however we will also perform chart reviews to identify predictors of completing appropriate followup.

Official Title
-----------------
Improving Followup of Positive Fecal Occult Blood Tests

Conditions
-----------------
Colorectal Cancer

Intervention / Treatment
-----------------
* Behavioral: Patient mailing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with positive fecal occult blood test during 2004, 2005, and 2006; and no colonoscopy following this test result Exclusion Criteria: Patients with active cardiopulmonary disease or limited life expectancy due to severe illness such as malignancy Colonoscopy within 5 years prior to positive fecal occult blood test Age > 80 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Patients will receive a mailing recommending colonoscopy, followed by a telephone outreach | Behavioral: Patient mailing<br>* Patient will receive a mailing recommending colonoscopy, followed by telephone outreach<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Performance of colonoscopy |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Colorectal cancer, Fecal occult blood test, Abnormal test result, Missed diagnosis, Delayed diagnosis
A Study of Gaboxadol in Primary Insomnia

Study Overview
=================
Brief Summary
-----------------
To evaluate the efficacy safety and tolerability of gaboxadol in primary insomnia.

Detailed Description
-----------------
To compare hypnotic efficacy of gaboxadol with placebo in elderly outpatients with primary insomnia

Official Title
-----------------
A Prospective Randomised Double-Blind Parallel-Group Placebo-Controlled Study of Gaboxadol in Primary Insomnia

Conditions
-----------------
Primary Insomnia

Intervention / Treatment
-----------------
* Drug: Gaboxadol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with a diagnosis of primary insomnia

Ages Eligible for Study
-----------------
Minimum Age: 66 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Gaboxadol|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy |  |  | 
| Safety |  |  | 
| Tolerability |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Primary insomnia